By [Your Publication Name] Staff
Published: October 24, 2025
The narrative surrounding breast cancer is frequently dominated by stories of "survivorship"—of finishing chemotherapy, ringing a bell, and returning to a life defined by the absence of disease. However, for a significant and often overlooked segment of the patient population, the finish line does not exist. For women like Miriam Sabo, the diagnosis of Stage 4 breast cancer represents not a temporary battle, but a permanent recalibration of existence.
As of October 2025, Sabo’s journey serves as a poignant case study in the shifting paradigm of metastatic breast cancer (MBC). Diagnosed at the age of 42 with "de novo" metastatic disease, Sabo has spent the last six and a half years navigating a medical reality that is increasingly viewed not as an immediate death sentence, but as a chronic, non-curative condition. Her story highlights the critical intersection of medical intervention, psychological resilience, and the specialized support systems required to sustain life on the "forever" treatment plan.
Main Facts: Redefining the Stage 4 Narrative
Metastatic Breast Cancer, also known as Stage 4, occurs when cancer cells break away from the original tumor in the breast and travel through the lymphatic system or bloodstream to other parts of the body. In Sabo’s case, the cancer had already colonized her liver at the time of her initial presentation—a scenario known as de novo metastatic breast cancer.
According to clinical data, approximately 6% of women are metastatic at their initial diagnosis. For this demographic, there is no "Stage 1" or "Stage 2" precursor; the disease is advanced from the outset. This distinction is vital for understanding the psychological weight of the diagnosis. While early-stage patients focus on "beating" the disease, MBC patients must accept a "non-curative" status.
Sabo, who rejects the term "terminal" in favor of "non-curative," emphasizes that her narrative does not fit the standard "pink ribbon" imagery. "The image of fighter gloves and slogans of ‘we’re gonna beat this’ were not going to be my narrative," Sabo explained. Instead, the reality is one of indefinite treatment. The goal of modern oncology for MBC is to extend life while maintaining the highest possible quality, effectively treating the cancer like a chronic illness such as diabetes or heart disease, albeit with significantly higher stakes.
Chronology: Six and a Half Years of "Forever"
The timeline of Miriam Sabo’s experience offers a window into the endurance required of MBC patients.
The Initial Shock (Circa 2019)
At age 42, Sabo received the diagnosis that the cancer had spread to her liver. The immediate aftermath was characterized by a search for information and a grappling with statistics. In the metastatic community, patients are frequently warned against "Googling" their prognosis, as historical data often fails to account for the rapid advancements in targeted therapies and immunotherapy seen in the last five years.
Integration with Sharsheret
Early in her journey, Sabo identified the need for a specialized "cancer team" that extended beyond oncology and radiology. She turned to Sharsheret, a national Jewish non-profit organization that provides support to women and families facing breast and ovarian cancer. Having previously contacted the organization regarding BRCA testing (for which she tested negative), Sabo re-engaged with them at a deeper level.
She was paired with Rachel, a social worker who provided a "sounding board" for the psychological turbulence of those early weeks. This period was marked by the transition from a healthy individual to a patient who would be in treatment for the remainder of her life.
The Milestone Years (2019–2025)
Over the subsequent 6.5 years, Sabo’s life became a testament to the possibility of "living with" rather than just "dying from" MBC. During this period, she reached milestones that many in her position fear they will miss:
- Watching her four children grow into adulthood.
- Attending multiple graduations.
- Celebrating the weddings of two of her children.
- Engaging in the "day-in and day-out" moments of domestic life.
Advocacy and Peer Support
Recognizing the unique isolation of the MBC experience, Sabo transitioned from a recipient of support to a provider. Encouraged by Rachel and Bonnie, the head of Sharsheret’s "Embrace" program (specifically designed for those living with advanced cancer), Sabo became a peer supporter. This role involves mentoring other women diagnosed with MBC, helping them navigate the complexities of a non-curative diagnosis.
Supporting Data: The Reality of MBC in 2025
The statistics surrounding MBC are both sobering and, increasingly, a source of cautious optimism.
Survival Trends
While MBC remains the leading cause of breast cancer deaths, the median survival rate has been steadily climbing. In the early 1990s, the median survival for MBC was roughly 20 months. Today, due to the advent of CDK4/6 inhibitors, HER2-targeted therapies, and improved bone-strengthening agents, many patients live five, ten, or even fifteen years post-diagnosis. Sabo’s 6.5-year survival places her within a growing cohort of "long-term" metastatic survivors.
The "De Novo" Factor
The 6% of patients diagnosed de novo face a different clinical trajectory than those whose cancer recurs years after early-stage treatment. Research suggests that de novo patients may sometimes have a better response to initial systemic therapies because their tumors have not yet developed resistance to common treatments like tamoxifen or aromatase inhibitors.
The Psychological Burden
Studies published in the Journal of Clinical Oncology indicate that MBC patients report significantly higher levels of distress, anxiety, and depression compared to early-stage patients. The "forever treatment" model creates a state of "scanxiety"—the chronic stress associated with the three-month intervals of PET or CT scans that determine if a current treatment remains effective or if the cancer has progressed.
Official Responses: The Role of Support Frameworks
The medical and advocacy communities have had to evolve to meet the needs of patients like Sabo. Organizations like Sharsheret have developed specific protocols for the metastatic community that differ from general cancer support.
The Sharsheret "Embrace" Program
Bonnie Beckoff, Director of Support Services at Sharsheret, has noted that the "Embrace" program was created because the needs of the metastatic community are often drowned out during Breast Cancer Awareness Month. "While the world is focused on ‘curing’ and ‘surviving,’ our Embrace members are focused on ‘living’ and ‘sustaining,’" the organization notes.
The program provides:
- Specialized Social Work: Focusing on end-of-life planning and "legacy" work while simultaneously supporting active living.
- Peer Support: Pairing newly diagnosed MBC patients with veterans of the disease to provide practical advice on managing side effects and emotional fatigue.
- Financial and Genetic Counseling: Addressing the long-term economic impact of perpetual treatment.
The Clinical Shift
Oncologists are increasingly adopting a "palliative-start" approach. This does not mean hospice; rather, it involves integrating palliative care (symptom management) early in the treatment process to ensure that the "forever" Sabo speaks of is defined by quality of life, not just the quantity of days.
Implications: The "No Expiration Date" Philosophy
Miriam Sabo’s motto—"I’m not milk; there’s no expiration date stamped on me"—represents a vital shift in the sociology of cancer. As more patients live longer with metastatic disease, the societal definition of a "cancer patient" is being forced to change.
The Shift from "Fighter" to "Manager"
The traditional "warrior" rhetoric of cancer—fighting, winning, and losing—is often viewed as reductive by those with MBC. If the cancer is non-curative, "winning" cannot mean the eradication of the disease. Instead, Sabo’s narrative suggests that "winning" is defined by the ability to remain present for life’s milestones despite the presence of disease. This shifts the focus from the biology of the tumor to the biography of the person.
The Importance of Faith and Community
For Sabo, her faith has been an anchor. She notes that she holds onto her belief that "G-d’s plans are always for good, even in the hardest of moments." This spiritual resilience, combined with the structural support of the Sharsheret community, highlights the necessity of a holistic approach to metastatic care. Medical science can provide the drugs to stabilize the liver, but community and faith provide the reason to keep taking them.
Future Outlook
As we move further into late 2025, the focus of breast cancer research is increasingly turning toward "oligometastatic" disease—cases where there are only a few metastatic spots—and whether these can be treated with curative intent. For the broader MBC population, the goal remains the "chronicization" of the disease.
Miriam Sabo’s story is a reminder that statistics are not destiny. While she is acutely aware that she is "living past the statistics," her 6.5-year journey stands as a beacon for the thousands of women diagnosed each year who are told their cancer is Stage 4. Her life demonstrates that while a diagnosis may be non-curative, it is not the end of a life’s meaning, its growth, or its joy.
In the landscape of 2025, the "expiration date" is being pushed back further than ever before, allowing mothers to see weddings, advocates to find their voices, and patients to live lives that are defined by much more than a diagnosis.
About the Author
